These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Site-Specific Conjugation of Auristatins onto Engineered scFv Using Second Generation Maleimide to Target HER2-positive Breast Cancer in Vitro. Aubrey N; Allard-Vannier E; Martin C; Bryden F; Letast S; Colas C; Lakhrif Z; Collinet N; Dimier-Poisson I; Chourpa I; Viaud-Massuard MC; Joubert N Bioconjug Chem; 2018 Nov; 29(11):3516-3521. PubMed ID: 30352511 [TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates. Jackson D; Atkinson J; Guevara CI; Zhang C; Kery V; Moon SJ; Virata C; Yang P; Lowe C; Pinkstaff J; Cho H; Knudsen N; Manibusan A; Tian F; Sun Y; Lu Y; Sellers A; Jia XC; Joseph I; Anand B; Morrison K; Pereira DS; Stover D PLoS One; 2014; 9(1):e83865. PubMed ID: 24454709 [TBL] [Abstract][Full Text] [Related]
9. Site-specific antibody-polymer conjugates for siRNA delivery. Lu H; Wang D; Kazane S; Javahishvili T; Tian F; Song F; Sellers A; Barnett B; Schultz PG J Am Chem Soc; 2013 Sep; 135(37):13885-91. PubMed ID: 23924037 [TBL] [Abstract][Full Text] [Related]
10. Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs. Behrens CR; Ha EH; Chinn LL; Bowers S; Probst G; Fitch-Bruhns M; Monteon J; Valdiosera A; Bermudez A; Liao-Chan S; Wong T; Melnick J; Theunissen JW; Flory MR; Houser D; Venstrom K; Levashova Z; Sauer P; Migone TS; van der Horst EH; Halcomb RL; Jackson DY Mol Pharm; 2015 Nov; 12(11):3986-98. PubMed ID: 26393951 [TBL] [Abstract][Full Text] [Related]
11. Recent Chemical Approaches for Site-Specific Conjugation of Native Antibodies: Technologies toward Next-Generation Antibody-Drug Conjugates. Yamada K; Ito Y Chembiochem; 2019 Nov; 20(21):2729-2737. PubMed ID: 30973187 [TBL] [Abstract][Full Text] [Related]
13. Bispecific Antibodies and Antibody-Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs. Andreev J; Thambi N; Perez Bay AE; Delfino F; Martin J; Kelly MP; Kirshner JR; Rafique A; Kunz A; Nittoli T; MacDonald D; Daly C; Olson W; Thurston G Mol Cancer Ther; 2017 Apr; 16(4):681-693. PubMed ID: 28108597 [TBL] [Abstract][Full Text] [Related]
14. Development and biological assessment of MMAE-trastuzumab antibody-drug conjugates (ADCs). Yaghoubi S; Gharibi T; Karimi MH; Sadeqi Nezhad M; Seifalian A; Tavakkol R; Bagheri N; Dezhkam A; Abdollahpour-Alitappeh M Breast Cancer; 2021 Jan; 28(1):216-225. PubMed ID: 32889587 [TBL] [Abstract][Full Text] [Related]
15. Engineering a HER2-specific antibody-drug conjugate to increase lysosomal delivery and therapeutic efficacy. Kang JC; Sun W; Khare P; Karimi M; Wang X; Shen Y; Ober RJ; Ward ES Nat Biotechnol; 2019 May; 37(5):523-526. PubMed ID: 30936563 [TBL] [Abstract][Full Text] [Related]
16. On the use of DNA as a linker in antibody-drug conjugates: synthesis, stability and in vitro potency. Dovgan I; Ehkirch A; Lehot V; Kuhn I; Koniev O; Kolodych S; Hentz A; Ripoll M; Ursuegui S; Nothisen M; Cianférani S; Wagner A Sci Rep; 2020 May; 10(1):7691. PubMed ID: 32376903 [TBL] [Abstract][Full Text] [Related]
17. Impact of cathepsin B-sensitive triggers and hydrophilic linkers on in vitro efficacy of novel site-specific antibody-drug conjugates. Bryden F; Martin C; Letast S; Lles E; Viéitez-Villemin I; Rousseau A; Colas C; Brachet-Botineau M; Allard-Vannier E; Larbouret C; Viaud-Massuard MC; Joubert N Org Biomol Chem; 2018 Mar; 16(11):1882-1889. PubMed ID: 29473076 [TBL] [Abstract][Full Text] [Related]
18. Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody-drug conjugates. Gianolio DA; Rouleau C; Bauta WE; Lovett D; Cantrell WR; Recio A; Wolstenholme-Hogg P; Busch M; Pan P; Stefano JE; Kramer HM; Goebel J; Krumbholz RD; Roth S; Schmid SM; Teicher BA Cancer Chemother Pharmacol; 2012 Sep; 70(3):439-49. PubMed ID: 22821053 [TBL] [Abstract][Full Text] [Related]
19. Trastuzumab-DM1: a clinical update of the novel antibody-drug conjugate for HER2-overexpressing breast cancer. Barginear MF; John V; Budman DR Mol Med; 2013 Jan; 18(1):1473-9. PubMed ID: 23196784 [TBL] [Abstract][Full Text] [Related]
20. Binding and functional profiling of antibody mutants guides selection of optimal candidates as antibody drug conjugates. Zwaagstra JC; Sulea T; Baardsnes J; Radinovic S; Cepero-Donates Y; Robert A; O'Connor-McCourt MD; Tikhomirov IA; Jaramillo ML PLoS One; 2019; 14(12):e0226593. PubMed ID: 31891584 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]